{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:25:43Z","timestamp":1769844343622,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T00:00:00Z","timestamp":1670112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T00:00:00Z","timestamp":1670112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda (China) International Trading Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12325-022-02355-3","type":"journal-article","created":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T11:02:27Z","timestamp":1670151747000},"page":"705-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct05013190","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Wenming","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,4]]},"reference":[{"key":"2355_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"2355_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","volume":"374","author":"MS Raab","year":"2009","unstructured":"Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324\u201339.","journal-title":"Lancet"},{"key":"2355_CR3","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA. 2021;71:7\u201333.","journal-title":"CA."},{"key":"2355_CR4","unstructured":"Myeloma\u2014Cancer Stat Facts [Internet]. SEER. [cited 21 Apr 2021]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"2355_CR5","doi-asserted-by":"publisher","unstructured":"Wang S, Xu L, Feng J, Liu Y, Liu L, Wang J, et\u00a0al. Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol [Internet]. 2020 [cited 21 Apr 2021];9. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fonc.2019.01513\/full#B1","DOI":"10.3389\/fonc.2019.01513\/full#B1"},{"key":"2355_CR6","unstructured":"WHO. Globocan 2020 World Fact Sheet: China. [Internet]. [cited 21 Apr 2021]. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/160-china-fact-sheets.pdf"},{"key":"2355_CR7","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et\u00a0al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122\u20138.","journal-title":"Leukemia"},{"key":"2355_CR8","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015;385:2197\u2013208.","journal-title":"Lancet"},{"key":"2355_CR9","doi-asserted-by":"publisher","first-page":"60656","DOI":"10.18632\/oncotarget.19269","volume":"8","author":"A Larocca","year":"2017","unstructured":"Larocca A, Mina R, Gay F, Bringhen S, Boccadoro M. Emerging drugs and combinations to treat multiple myeloma. Oncotarget. 2017;8:60656\u201372.","journal-title":"Oncotarget"},{"key":"2355_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-019-0823-5","volume":"12","author":"C Wu","year":"2019","unstructured":"Wu C, Zhang L, Brockman QR, Zhan F, Chen L. Chimeric antigen receptor T cell therapies for multiple myeloma. J Hematol Oncol. 2019;12:120.","journal-title":"J Hematol Oncol"},{"key":"2355_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et\u00a0al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38:775\u201383.","journal-title":"J Clin Oncol"},{"key":"2355_CR12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, et\u00a0al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 2014;15:1503\u201312.","journal-title":"Lancet Oncol"},{"key":"2355_CR13","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et\u00a0al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621\u201334.","journal-title":"N Engl J Med"},{"key":"2355_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et\u00a0al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519\u201327.","journal-title":"Lancet"},{"key":"2355_CR15","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","volume":"31","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Goldschmidt H, Rosi\u00f1ol L, Blad\u00e9 J, Lahuerta JJ, Cavo M, et\u00a0al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31:3279\u201387.","journal-title":"J Clin Oncol"},{"key":"2355_CR16","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et\u00a0al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075\u201385.","journal-title":"Lancet"},{"key":"2355_CR17","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","volume":"118","author":"P Moreau","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, et\u00a0al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118:5752\u20138 (quiz 5982).","journal-title":"Blood."},{"key":"2355_CR18","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00520-015-2644-6","volume":"23","author":"R Baz","year":"2015","unstructured":"Baz R, Lin HM, Hui A-M, Harvey RD, Colson K, Gallop K, et\u00a0al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer. 2015;23:2789\u201397.","journal-title":"Support Care Cancer"},{"key":"2355_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/1471-2407-14-496","volume":"14","author":"TR Osborne","year":"2014","unstructured":"Osborne TR, Ramsenthaler C, de Wolf-Linder S, Schey SA, Siegert RJ, Edmonds PM, et\u00a0al. Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC Cancer. 2014;14:496.","journal-title":"BMC Cancer"},{"key":"2355_CR20","doi-asserted-by":"publisher","first-page":"e910","DOI":"10.1016\/j.clml.2020.06.024","volume":"20","author":"S Manda","year":"2020","unstructured":"Manda S, Yimer HA, Noga SJ, Girnius S, Yasenchak CA, Charu V, et\u00a0al. Feasibility of long-term proteasome inhibition in multiple myeloma by in-class transition from bortezomib to ixazomib. Clin Lymphoma Myeloma Leuk. 2020;20:e910\u201325.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2355_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen W-M, et\u00a0al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34:224\u201333.","journal-title":"Leukemia"},{"key":"2355_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","volume":"20","author":"A Chari","year":"2020","unstructured":"Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, et\u00a0al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:8-17.e16.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2355_CR23","doi-asserted-by":"crossref","unstructured":"Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et\u00a0al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J [Internet]. 2018 [cited 23 Apr 2021];8. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6226527\/","DOI":"10.1038\/s41408-018-0141-0"},{"key":"2355_CR24","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00277-020-04234-9","volume":"99","author":"J Li","year":"2020","unstructured":"Li J, Bao L, Xia Z, Wang S, Zhou X, Ding K, et\u00a0al. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol. 2020;99:2589\u201398.","journal-title":"Ann Hematol"},{"key":"2355_CR25","doi-asserted-by":"publisher","first-page":"8935","DOI":"10.2147\/CMAR.S261887","volume":"12","author":"K Ding","year":"2020","unstructured":"Ding K, Yu H, Shao Y-Y, Li L-Y, Wang C-M, Song J, et\u00a0al. Real-world data on the efficacy and safety of ixazomib-based therapy in multiple myeloma: a single-center study in China. Cancer Manag Res. 2020;12:8935\u201341.","journal-title":"Cancer Manag Res"},{"key":"2355_CR26","first-page":"322","volume":"45","author":"Y He","year":"2020","unstructured":"He Y, Zhang K, Zou L, Chen S, Jiang D, Hu J, et\u00a0al. Clinical study on ixazomib in the treatment of multiple myeloma. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020;45:322\u20137.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02355-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02355-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02355-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T07:19:37Z","timestamp":1675408777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02355-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2355"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02355-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,4]]},"assertion":[{"value":"11 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}